An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomized controlled trial

Primary tabs

SCIENCE
Abstracts
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomized controlled trial
Key Take-Away: 

Rituximab is a biological therapy for Rheumatoid arthritis (RA) which reduces joint pain and swelling by removing B cells, responsible for inflammation. In this study, the investigators were able to produce fruitful results with an extra dose of rituximab to the RA patients with incomplete B cell depletion.

Since clinical non-response to 2×1000 mg rituximab has previously been found to be associated with incomplete B cell depletion, we determined, in a randomized controlled proof of concept study, whether patients with initial incomplete B cell depletion would benefit from an additional infusion of rituximab at week 4.

ABSTRACT: 
Background: 

Since clinical non-response to 2×1000 mg rituximab has previously been found to be associated with incomplete B cell depletion, we determined, in a randomized controlled proof of concept study, whe

Since clinical non-response to 2×1000 mg rituximab has previously been found to be associated with incomplete B cell depletion, we determined, in a randomized controlled proof of concept study, whether patients with initial incomplete B cell depletion would benefit from an additional infusion of rituximab at week 4.

Expand section
Methods: 

Patients with active RA despite methotrexate received a first infusion of rituximab 1000 mg and were tested for persistent B cells using highly sensitive flow cytometry on day 15.

Patients with active RA despite methotrexate received a first infusion of rituximab 1000 mg and were tested for persistent B cells using highly sensitive flow cytometry on day 15. All received a second infusion of 1 g (according to license), but patients with persistent B cells were subsequently randomized double-blind to receive, 2 weeks later, either a third infusion of 1000 mg rituximab or placebo. Clinical response was determined by European League against Rheumatism (EULAR) and American College of Rheumatology (ACR) criteria.

Expand section
Results: 

Baseline characteristics were balanced between groups.

Baseline characteristics were balanced between groups. Treatment with 3×1000 mg rituximab resulted in significantly greater depletion (lower B cell and plasmablast numbers between 8 and 28 weeks) paralleled by significantly better EULAR and ACR20 response rates at 40 weeks (p=0.035 and p=0.027, respectively) and 52 weeks (p=0.021 and p=0.043, respectively) compared with 2×1000 mg. Immunoglobulin titres remained stable in both arms, and adverse event rates were balanced.

Expand section
Conclusion: 

In rituximab-treated patients with incomplete B cell depletion (predictive of poor response), an extra 1000 mg infusion of rituximab at 4 weeks produced both better depletion and clinical responses than placebo with no worsening of safety.

In rituximab-treated patients with incomplete B cell depletion (predictive of poor response), an extra 1000 mg infusion of rituximab at 4 weeks produced both better depletion and clinical responses than placebo with no worsening of safety. Degree of depletion is an important, but modifiable, determinant of response.

Expand section
Ann Rheum Dis 2015; 74:1195-1201 
Exploratory, Rituximab, Rheumatoid Arthritis, Joints, Monoclonal Antibody, Randomized Controlled Trial, EULAR, ACR20 Response Rates
Log in or register to post comments